Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture

Authors: Turk, James R., Deaton, Aimee M., Yin, Jun, Stolina, Marina, Felx, Melanie, Boyd, Gabrielle, Bienvenu, Jean-Guy, Varela, Aurore, Guillot, Martin, Holdsworth, Gill, Wolfreys, Alison, Dwyer, Denise, Kumar, Sheetal V., de Koning, Emily M., Qu, Yusheng, Engwall, Michael, Locher, Kathrin, Ward, Lucas D., Glaus, Charles, He, Yudong D., Boyce, Rogely Waite

Source: In Regulatory Toxicology and Pharmacology August 2020 115